

Selected Bibliography for:

PIPG SYMPOSIUM 2017

**A HEALTHY DOSE OF IP:
THE EVOLVING LEGAL LANDSCAPE OF THE HEALTH FIELD
MARCH 16, 2017**

Pharmaceuticals

Hannah Brennan, *The Cost of Confusion: The Paradox of Trademarked Pharmaceuticals*, 22 MICH. TELECOMM. & TECH. L. REV. 1 (2015), available [here](#).

Matthew M. D'Amore, et al., *FDA (Finally!) Issues New Regulations to Clarify Pharmaceutical Patent Litigation: How to Use Patent "Use Codes,"* 29(1) INTELL. PROP. & TECH. L.J. 10 (2017), available [here](#).

Patricia M. Danzon & Li-Wei Chao, *Does Regulation Drive Out Competition in Pharmaceutical Markets?*, 43 J.L. & ECON. 311 (2000), available [here](#).

Anna Dontje, *Rethinking Trips: The Future of Pharmaceutical Patents*, 33 WIS. INT'L L.J. 380 (2015), available [here](#).

Robin Feldman & Evan Frondorf, *Drug Wars: A New Generation of Generic Pharmaceutical Delay*, 53 HARV. J. ON LEGIS. 499 (2016), available [here](#).

Arlen W. Langvardt, *Generic Pharmaceuticals and the "Unfortunate Hand" Dealt to Harmed Consumers: The Emerging State Court Resistance*, 17 MINN. J.L. SCI. & TECH. 565 (2016), available [here](#).

Lars Noah, *State Affronts to Federal Primacy in the Licensure of Pharmaceutical Products*, 2016 MICH. ST. L. REV. 1 (2016), available [here](#).

Valentina S. Vadi, *Towards a New Dialectics: Pharmaceutical Patents, Public Health and Foreign Direct Investments*, 5 NYU J. INTELL. PROP. & ENT. L. 113 (2015), available [here](#).

Liza S. Vertinsky, *Patents, Partnerships, and the Pre-Competitive Collaboration Myth in Pharmaceutical Innovation*, 48 U.C. DAVIS L. REV. 1509 (2015), available [here](#).

Medical Devices

John R. Allison, et al., *Our Divided Patent System*, 82 U. CHI. L. REV. 1073 (2015), available [here](#).

Robin Feldman & Mark A. Lemley, *Do Patent Licensing Demands Mean Innovation?*, 101 IOWA L. REV. 137 (2015), available [here](#).

Eric Lindenfeld, *3D Printing of Medical Devices: CAD Designers as the Most Realistic Target for Strict, Product Liability Lawsuits*, 85 UMKC L. REV. 79 (2016), available [here](#).

W. Nicholson Price II, *Black-Box Medicine*, 28 HARV. J.L. & TECH. 419 (2015), available [here](#).

Benjamin N. Roin, *The Case for Tailoring Patent Awards Based On Time-To-Market*, 61 UCLA L. REV. 672 (2014), available [here](#).

Randy V. Sabett, *The Effects of Technology Convergence and Public Key Infrastructure on the Practice of Law*, 7 U. BALT. INTELL. PROP. L.J. 143 (1999), available [here](#).

Jasper L. Tran, *The Law and 3D Printing*, 31 J. MARSHALL J. INFO. TECH. & PRIVACY L. 505 (2015), available [here](#).

Brian P. Wallenfelt, *Hatch-Waxman and Medical Devices*, 40 WM. MITCHELL L. REV. 1407 (2014), available [here](#).

_____, *Is It Time For An Abbreviated Premarket Approval For Medical Devices?*, 39 WM. MITCHELL L. REV. 1026 (2013), available [here](#).

Patents and Personalized Medicine

Kristin Beale, *The CRISPR Patent Battle: Who Will Be “Cut” Out of Patent Rights to One of the Greatest Scientific Discoveries of Our Generation?*, 2016 B.C. INTELL. PROP. & TECH. F. 1 (2016), available [here](#).

Leland L. Black, *Patenting and Protecting Personalized Medicine Innovation Post-Mayo, Myriad, and Limelight*, 95 N.C. L. REV. 493 (2017), available [here](#).

Dan L. Burk, *Patents As Data Aggregators in Personalized Medicine*, 21 B.U. J. SCI. & TECH. L. 233 (2015), available [here](#).

Robin Feldman, *The CRISPR Revolution: What Editing Human DNA Reveals about the Patent System's DNA*, 64 UCLA L. REV. DISCOURSE 392 (2016), available [here](#).

Christopher M. Holman, *The Critical Role of Patents in the Development, Commercialization and Utilization of Innovative Genetic Diagnostic Tests and Personalized Medicine*, 21 B.U. J. SCI. & TECH. L. 297 (2015), available [here](#).

Antoinette F. Konski, *The Utility Rejection in Biotechnology and Pharmaceutical Prosecution Practice*, 76 J. PAT. & TRADEMARK OFF. SOC'Y 821 (1994), available [here](#).

Leah Octavio, *The Patent Eligibility of Personalized Medicine Technologies*, 35 J. LEGAL MED. 423 (2014), available [here](#).

Rachel E. Sachs, *Innovation Law and Policy: Preserving the Future of Personalized Medicine*, 49 U.C. DAVIS L. REV. 1881 (2016), available [here](#).

Charlene A. Stern-Dombal, *Tripping Over Trips: Is Compulsory Licensing Under Ebay at Odds with U.S. Statutory Requirements and Trips?*, 41 SUFFOLK U. L. REV. 249 (2007), available [here](#).

James R. Whittle, *Tailored Treatment, Tailored Enforcement: Protecting Innovation in Personalized Medicine from a Patent-Protection Loophole*, 84 GEO. WASH. L. REV. 480 (2016), available [here](#).